Featured Publications
Integrating population and single-cell variations in vaccine responses identifies a naturally adjuvanted human immune setpoint
Mulè M, Martins A, Cheung F, Farmer R, Sellers B, Quiel J, Jain A, Kotliarov Y, Bansal N, Chen J, Schwartzberg P, Tsang J. Integrating population and single-cell variations in vaccine responses identifies a naturally adjuvanted human immune setpoint. Immunity 2024, 57: 1160-1176.e7. PMID: 38697118, DOI: 10.1016/j.immuni.2024.04.009.Peer-Reviewed Original ResearchConceptsTranscriptional statesVaccine responseSingle-cell profiling methodsSingle-cell variationAS03-adjuvanted vaccineUnadjuvanted influenza vaccineResponse to lipopolysaccharide stimulationB cell signaturesCD14<sup>+</sup> monocytesSingle-cell levelBiological insightsUnadjuvanted vaccineAS03-adjuvantedInfluenza vaccineResponse phenotypesCITE-seqInnate subsetsAdjuvant developmentHigh antibody respondersDay 1Antibody respondersLipopolysaccharide stimulationVaccineCorrelation networkHuman population
2024
Acute and persistent responses after H5N1 vaccination in humans
Apps R, Biancotto A, Candia J, Kotliarov Y, Perl S, Cheung F, Farmer R, Mulè M, Rachmaninoff N, Chen J, Martins A, Shi R, Zhou H, Bansal N, Schum P, Olnes M, Milanez-Almeida P, Han K, Sellers B, Cortese M, Hagan T, Rouphael N, Pulendran B, King L, Manischewitz J, Khurana S, Golding H, van der Most R, Dickler H, Germain R, Schwartzberg P, Tsang J. Acute and persistent responses after H5N1 vaccination in humans. Cell Reports 2024, 43: 114706. PMID: 39235945, DOI: 10.1016/j.celrep.2024.114706.Peer-Reviewed Original ResearchH5N1 influenza vaccineImpact vaccine responsesTime pointsAdjuvant AS03H5N1 vaccineInfluenza vaccineT cellsVaccine responseVaccinated cohortHigh antibody respondersImmune stateVaccine antigensMultiple time pointsSingle-cell profilingInitial vaccinationSystems immunologyVaccinePersistent responseSurface proteinsCell type-specific signaturesChromatin accessibilityTranscription factorsH5N1DaysAS03Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus
Khurana S, King L, Manischewitz J, Posadas O, Mishra A, Liu D, Beigel J, Rappuoli R, Tsang J, Golding H. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nature Medicine 2024, 30: 2771-2776. PMID: 39013430, DOI: 10.1038/s41591-024-03189-y.Peer-Reviewed Original ResearchCross-neutralizing antibodiesH5N1 vaccineNeutralizing antibody responsesVaccination of adultsDevelopment of effective vaccinesGlobal public health threatHPAI H5N1Influenza virusSeroconversion ratesH5N1Neutralizing antibodiesCross-reactive bindingPublic health threatLicensed vaccinesHemagglutination inhibitionPublic health priorityAntibody responseEffective vaccineHPAIVaccineAntibodiesDoseHealth priorityVirusHealth threat
2022
Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses
Hagan T, Gerritsen B, Tomalin LE, Fourati S, Mulè MP, Chawla DG, Rychkov D, Henrich E, Miller HER, Diray-Arce J, Dunn P, Lee A, Levy O, Gottardo R, Sarwal M, Tsang J, Suárez-Fariñas M, Sékaly R, Kleinstein S, Pulendran B. Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses. Nature Immunology 2022, 23: 1788-1798. PMID: 36316475, PMCID: PMC9869360, DOI: 10.1038/s41590-022-01328-6.Peer-Reviewed Original ResearchConceptsAntibody responseDay 1Vaccine-induced antibodiesYellow fever vaccineHuman immune responseMechanisms of immunityB cell activationTranscriptional atlasFever vaccineDifferent vaccinesSystems vaccinologyImmune responseMost vaccinesDay 7Cell activationInnate immunityVaccineVaccinationImmunityCommon predictorsMolecular signaturesResponsePlasmablastsInterferonAntibodiesThe Immune Signatures data resource, a compendium of systems vaccinology datasets
Diray-Arce J, Miller HER, Henrich E, Gerritsen B, Mulè MP, Fourati S, Gygi J, Hagan T, Tomalin L, Rychkov D, Kazmin D, Chawla DG, Meng H, Dunn P, Campbell J, Sarwal M, Tsang J, Levy O, Pulendran B, Sekaly R, Floratos A, Gottardo R, Kleinstein S, Suárez-Fariñas M. The Immune Signatures data resource, a compendium of systems vaccinology datasets. Scientific Data 2022, 9: 635. PMID: 36266291, PMCID: PMC9584267, DOI: 10.1038/s41597-022-01714-7.Peer-Reviewed Original ResearchConceptsHuman Immunology Project ConsortiumDifferent vaccinesCost-effective public health interventionsGene Expression OmnibusInfection-induced morbiditySystems immunology approachPublic health interventionsMultiple relevant studiesVaccine responsesHealth interventionsVaccineRelevant studiesVaccine discoveryUnderstanding of mechanismsMolecular signaturesImmPortSystems immunologyImmunologyStudy dataTraditional immunologyMorbidityCohortImmunogenicityMortalityRelease
2018
AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
Khurana S, Coyle E, Manischewitz J, King L, Gao J, Germain R, Schwartzberg P, Tsang J, Golding H. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. Npj Vaccines 2018, 3: 40. PMID: 30302282, PMCID: PMC6167326, DOI: 10.1038/s41541-018-0076-2.Peer-Reviewed Original ResearchAntibody responseWhole genome-fragment phage display librariesGenome-fragment phage display librariesNeuraminidase inhibition antibody titersVaccine-induced antibody responsesFragment phage display librariesHeterologous H5N1 strainsPolyclonal antibody responsePandemic influenza strainsAffinity maturationNAI titerUnadjuvanted vaccineAntibody titersNeutralization titersSeasonal strainsVaccine platformImmune responseInfluenza strainsAS03Antibody affinity maturationFuture vaccinesImmune memoryViral hemagglutininEpitope diversityVaccine